



Financial Tear Sheet

CORPORATE PROFILE

Delcath Systems, Inc. (OTCQB-DCTH) Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM), and plans to initiate a global registration trial for intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.

PRIMARY IR CONTACT

Delcath Investor Relations

E-mail:

investorrelations@delcath.com


STOCK PERFORMANCE

DCTH (Common Stock)

Exchange	OTCQB (US Dollar)
Price	\$0.29
Change (%)	▼ 0.01 (3.33%)
Volume	151,925
52 Week Low	\$0.23
Market Cap	\$3,215,219
Rolling EPS	-267.95
PE Ratio	N/A
Shares Outstanding	11,163,954

Data as of 02/20/19 3:59 p.m. ET

■ DELCATH SYS INC
as of 2/19/2019



EDGAROnline

RECENT HEADLINES & EVENTS

02/11/19

Delcath Announces Health Authority Approval for CHEMOSAT in Brazil

There are currently no events scheduled.

02/08/19


Delcath Announces Acceptance of Abstract for Oral Presentation at ECIO 2019

12/26/18

Delcath Announces Commercial Licensing Agreement for

ANALYST ESTIMATES / RATINGS

Mean Recommendation: **2.0**



Unable to fulfill request.

SEC FILINGS

Filing Date	Form
02/14/19	SC 13G/A
02/11/19	8-K
02/07/19	8-K
02/05/19	4

CORPORATE GOVERNANCE

Jennifer Simpson, PhD., M.S.N., C.R.N.P.	President and Chief Executive Officer
John Purpura	Executive Vice President Regulatory Affairs, Quality Assurance
Barbra C. Keck	Chief Financial Officer

OWNERSHIP SUMMARY

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	10	.55	1.9	212,260
Mutual Fund	1	.00	0.0	2,187
Insider *	5	.07	0.3	34,328

*Insider values reflect direct beneficial ownership.

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Hudson Bay Capital Management LP	112,240	1.0	92,584	12/31/18
Ayrton Capital LLC	61,720	0.6	61,482	02/13/18
Rueckert (William Dodge)	9,709	0.1	9,708	09/28/18
Simpson (Jennifer K)	7,500	0.1	7,499	09/28/18
Keck (Barbra C)	7,500	0.1	7,499	09/28/18
Stoll (Roger G)	5,901	0.1	5,900	09/28/18
Purpura (John)	5,501	0.1	5,500	09/28/18
Invesco Capital Management LLC	2,187	0.0	1,971	12/31/18
Taglietti (Marco)	1	0.0	0	09/14/18
Gemmer Asset Management LLC	1	0.0	0	12/31/18

Powered by **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed